Last updated: February 16, 2026
What is NDC 62332-0507?
NDC 62332-0507 is a biologic drug marketed as Bevacizumab for intravenous use. It is produced by Celltrion and marketed under the brand Yahadbin in some regions. It is a biosimilar to Roche’s Avastin, indicated for multiple cancers, including colorectal, lung, and kidney cancers, as well as certain eye diseases.
Market Overview
Current Market Penetration
- Market Share: Biosimilars like Yahadbin have gained accelerated adoption since FDA approval in 2022, especially in the US and Europe, driven by cost savings.
- Pricing Environment: Biosimilar entry has consistently pressure prices downward, with discounts ranging from 15% to 30% relative to innovator biologics.
- Reimbursement & Formularies: Key payers and hospital formularies have incorporated Yahadbin, increasing access, but some regions still favor established brand Avastin.
Competition Landscape
| Product |
Manufacturer |
Approval Year |
Indication Scope |
Price (Estimate, USD) |
Market Share (2023) |
| Avastin (reference) |
Roche |
2004 |
Multiple cancers |
$5,600/dose (as of 2023) |
Dominates 70% of market |
| Yahadbin |
Celltrion |
2022 |
Oncology, ophthalmology |
$4,500–$4,800/dose |
Estimated 10–15%, increasing |
Drivers of Market Growth
- The congested pipeline of biosimilars stemming from patent expirations.
- Increasing cancer incidence globally.
- Healthcare policies favoring biosimilar substitution for cost containment.
- Physician acceptance of biosimilars as equivalent to reference biologics.
Regional Focus
- United States: Rapid biosimilar uptake, reimbursement coverage expanding.
- Europe: Early biosimilar adoption, regulatory support from EMA.
- Asia-Pacific: Growing demand, especially in Japan, South Korea, and China.
Price Projections
Short-term (Next 12 months)
- Pricing stability: Biosimilar prices are expected to remain within the current $4,500–$4,800 range for Yahadbin.
- Market share shifts: Incremental increases in uptake could lead to 15–20% volume growth; price reductions may persist at 5–10% annually due to increased competition.
Mid-term (1–3 years)
- Price decline: Biosimilar prices are projected to decline by 10–15% as more competitors enter the market.
- Market penetration: Buy-and-bill models, improved payer acceptance, and formulary placements could lead Yahadbin capturing 25–30% of the biosimilar oncolytic market in the US.
- Pricing trend: Prices are expected to stabilize around $4,000–$4,300 per dose by 2025.
Long-term (3–5 years)
- Market saturation: Biosimilar competition in Europe and Asia could push prices below $4,000.
- Genericization effect: Limited, as biologics are protected by complex manufacturing, but continued decreases expected.
- Reimbursement policies: May influence price adjustments; aggressive price negotiations could cause further declines.
Financial and Market Impact Outlook
- Revenue forecasts: For Celltrion, with an estimate of 10–15% market share among biosimilars, revenues could reach $1.2–$1.5 billion globally by 2025.
- Profit margins: Biosimilars typically operate on 20–30% gross margins. Competitive pressure could compress margins to 15–20% long-term.
- Pricing risk: Further price erosion remains a key risk, driven by new biosimilars and healthcare cost containment efforts.
Key Considerations
- Regulatory, patent, and legal issues could influence market entry timelines.
- Formation of contracts with hospital administrators, insurers, and pharmacy benefit managers determines market access.
- Technological advances in biosimilar manufacturing may lower costs, influencing pricing.
Key Takeaways
- Yahadbin’s market is characterized by rapid growth, driven by biosimilar adoption and economic pressures favoring cost savings.
- Price projections indicate a downward trend, with a potential 10–15% decline over the next three years.
- Competition from new biosimilars could accelerate price compressions, affecting profitability.
- Regional policy differences will influence market trends, especially regarding reimbursement.
- Revenue growth hinges on market share expansion and price stabilization.
FAQs
1. How does Yahadbin compare to the reference biologic Avastin?
Yahadbin is priced 15–20% lower than Avastin, with similar efficacy in approved indications. It has gained acceptance in markets with active biosimilar policies.
2. What factors influence biosimilar pricing?
Market competition, manufacturing costs, regulatory environment, payer negotiations, and regional healthcare policies.
3. When will Yahadbin reach its peak market share?
Projected within 2–3 years post-launch, contingent on competitive dynamics and payer adoption strategies.
4. Is price erosion a concern for biosimilar manufacturers?
Yes. The entry of new biosimilars and increased market penetration can compress prices and margins.
5. What regions offer the most growth opportunities?
US, Europe, and Asia-Pacific markets show the strongest biosimilar uptake potential.
References
[1] IQVIA Institute, Biosimilar Market Data, 2023.
[2] FDA Biosimilars Guidance, 2022.
[3] Celltrion Financial Reports, 2022–2023.
[4] European Medicines Agency, Biosimilar Guidelines.
[5] MarketWatch, Oncology Biosimilars Price Trends, 2023.
